브랜드 제네릭 시장 규모, 점유율, 동향 분석 보고서 : 약물 종류별, 용도별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2026-2033년)

Branded Generic Market Summary

The global branded generics market size was estimated at USD 276.98 billion in 2025 and is projected to reach USD 453.05 billion by 2033, growing at a CAGR of 6.5% from 2026 to 2033. The market continues to be shaped by strong demand in emerging economies, where prescription behavior favors named generics supported by physician familiarity and retail-driven distribution.

Asia Pacific remains the operational core, with manufacturers sustaining volumes through established brands in chronic therapies while selectively enhancing portfolios via fixed dose combinations and reformulations. In parallel, developed markets maintain limited but stable relevance for branded generics in segments where continuity of therapy and controlled substitution remain clinically important. For instance, in June 2024, Teva Pharmaceutical Industries Ltd. launched a generic version of Novo Nordisk's Victoza, targeting a diabetes segment that had generated approximately USD 1.6 billion in annual sales prior to market transition toward newer GLP 1 therapies. The launch illustrates how branded generic players continue to capture residual value from off patent molecules with established prescribing bases.

At the same time, the operating environment is becoming more constrained due to expanding tender based procurement, tighter pricing controls, and increasing regulatory compliance costs. These factors are gradually narrowing price differentiation between branded and unbranded generics, compelling manufacturers to focus on scale, portfolio selectivity, and complex generics to sustain profitability. Overall, the market reflects a balance between persistent demand for trusted brands and structural pressure toward commoditization.

Global Branded Generics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global branded generics market report based on drug class, application, route of administration, distribution channel, and region:

• Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
• Alkylating Agents
• Antimetabolites
• Hormones
• Anti-hypertensive
• Lipid Lowering drugs
• Anti-depressants
• Anti-psychotics
• Anti-epileptics
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Cardiovascular Diseases
• Neurological Diseases
• Gastrointestinal Diseases
• Dermatological diseases
• Acute and Chronic Pain
• Others
• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
• Topical
• Oral
• Parenteral
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy & Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1 Market Segmentation & Scope
• 1.2 Segment Definitions
  • 1.2.1 Drug Class
  • 1.2.2 Application
  • 1.2.3 Route of Administration
• 1.3 Estimates and Forecast Timeline
• 1.4 Research Methodology
• 1.5 Information Procurement
  • 1.5.1 Purchased Database
  • 1.5.2 GVR's Internal Database
  • 1.5.3 Secondary Sources
  • 1.5.4 Primary Research
• 1.6 Information Analysis
  • 1.6.1 Data Analysis Models
• 1.7 Market Formulation & Data Visualization
• 1.8 Model Details
  • 1.8.1 Commodity Flow Analysis
• 1.9 List of Secondary Sources
• 1.10 Objectives

Chapter 2. Executive Summary

• 2.1 Market Snapshot
• 2.2 Segment Snapshot
• 2.3 Competitive Landscape Snapshot

Chapter 3 Branded Generics Market Variables, Trends, & Scope

• 3.1 Market Lineage Outlook
• 3.2 Market Dynamics
  • 3.2.1 Market Driver Analysis
  • 3.2.2 Market Restraint Analysis
• 3.3 Business Environment Analysis
  • 3.3.1 Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1 Supplier Power
    • 3.3.1.2 Buyer Power
    • 3.3.1.3 Substitution Threat
    • 3.3.1.4 Threat of New Entrants
    • 3.3.1.5 Competitive Rivalry
  • 3.3.2 PESTLE Analysis
  • 3.3.3 Pipeline Analysis
  • 3.3.4 Patent Expiry Analysis
  • 3.3.5 Pricing Analysis

Chapter 4. Branded Generics Market: Drug Class Business Analysis

• 4.1. Drug Class Market Share, 2025 & 2033
• 4.2. Drug Class Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
• 4.4. Alkylating Agents
  • 4.4.1 Alkylating Agents Market, 2021 - 2033 (USD Million)
• 4.5. Antimetabolites
  • 4.5.1 Antimetabolites Market, 2021 - 2033 (USD Million)
• 4.6. Hormones
  • 4.6.1 Hormones Market, 2021 - 2033 (USD Million)
• 4.7. Anti-hypertensive
  • 4.7.1 Anti-hypertensive Market, 2021 - 2033 (USD Million)
• 4.8. Lipid Lowering drugs
  • 4.8.1 Lipid Lowering drugs Market, 2021 - 2033 (USD Million)
• 4.9. Anti-depressants
  • 4.9.1 Anti-depressants Market, 2021 - 2033 (USD Million)
• 4.10. Anti-psychotics
  • 4.10.1 Anti-psychotics Market, 2021 - 2033 (USD Million)
• 4.11. Anti-epileptics
  • 4.11.1 Anti-epileptics Market, 2021 - 2033 (USD Million)
• 4.12. Others
  • 4.12.1 Others Market, 2021 - 2033 (USD Million)

Chapter 5. Branded Generics Market: Application Business Analysis

• 5.1. Application Market Share, 2025 & 2033
• 5.2. Application Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Oncology
  • 5.4.1 Oncology Market, 2021 - 2033 (USD Million)
• 5.5. Cardiovascular Diseases
  • 5.5.1 Cardiovascular Diseases Market, 2021 - 2033 (USD Million)
• 5.6. Neurological Diseases
  • 5.6.1 Neurological Diseases Market, 2021 - 2033 (USD Million)
• 5.7. Gastrointestinal Diseases
  • 5.7.1 Gastrointestinal Diseases Market, 2021 - 2033 (USD Million)
• 5.8. Dermatological diseases
  • 5.8.1 Dermatological diseases Market, 2021 - 2033 (USD Million)
• 5.9. Acute and Chronic Pain
  • 5.9.1 Acute and Chronic Pain Market, 2021 - 2033 (USD Million)
• 5.10. Others
  • 5.10.1 Others Market, 2021 - 2033 (USD Million)

Chapter 6. Branded Generics Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2025 & 2033
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
• 6.4. Oral
  • 6.4.1 Oral Market, 2021 - 2033 (USD Million)
• 6.5. Topical
  • 6.5.1 Topical Market, 2021 - 2033 (USD Million)
• 6.4. Parenteral
  • 6.4.1 Parenteral Market, 2021 - 2033 (USD Million)
• 6.5. Others
  • 6.5.1 Others Market, 2021 - 2033 (USD Million)

Chapter 7. Branded Generics Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2025 & 2033
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
• 7.4. Hospital Pharmacy
  • 7.4.1 Hospital Pharmacy Market, 2021 - 2033 (USD Million)
• 7.5. Retail Pharmacy
  • 7.5.1 Retail Pharmacy Market, 2021 - 2033 (USD Million)
• 7.6. Online Pharmacy & Others
  • 7.6.1 Online Pharmacy & Others Market, 2021 - 2033 (USD Million)

Chapter 8. Branded Generics Market: Regional Estimates & Trend Analysis

• 8.1 Regional Market Share Analysis, 2025 & 2033
• 8.2 Regional Market Dashboard
• 8.3 Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 8.4 North America
  • 8.4.1 North America Branded Generics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 8.4.2 U.S.
    • 8.4.2.1 Key Country Dynamics
    • 8.4.2.2 Regulatory Framework
    • 8.4.2.3 Pricing Analysis
    • 8.4.2.4 U.S. Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3 Canada
    • 8.4.3.1 Key Country Dynamics
    • 8.4.3.2 Regulatory Framework
    • 8.4.3.3 Pricing Analysis
    • 8.4.3.4 Canada Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4 Mexico
    • 8.4.4.1 Key Country Dynamics
    • 8.4.4.2 Regulatory Framework
    • 8.4.4.3 Pricing Analysis
    • 8.4.4.4 Mexico Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5 Europe
  • 8.5.1 Europe Branded Generics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 8.5.2 UK
    • 8.5.2.1 Key Country Dynamics
    • 8.5.2.2 Regulatory Framework
    • 8.5.2.3 Pricing Analysis
    • 8.5.2.4 UK Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3 Germany
    • 8.5.3.1 Key Country Dynamics
    • 8.5.3.2 Regulatory Framework
    • 8.5.3.3 Pricing Analysis
    • 8.5.3.4 Germany Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4 France
    • 8.5.4.1 Key Country Dynamics
    • 8.5.4.2 Regulatory Framework
    • 8.5.4.3 Pricing Analysis
    • 8.5.4.4 France Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5 Italy
    • 8.5.5.1 Key Country Dynamics
    • 8.5.5.2 Regulatory Framework
    • 8.5.5.3 Pricing Analysis
    • 8.5.5.4 Italy Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6 Spain
    • 8.5.6.1 Key Country Dynamics
    • 8.5.6.2 Regulatory Framework
    • 8.5.6.3 Pricing Analysis
    • 8.5.6.4 Spain Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7 Denmark
    • 8.5.8.1 Key Country Dynamics
    • 8.5.8.2 Regulatory Framework
    • 8.5.8.3 Pricing Analysis
    • 8.5.8.4 Denmark Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.8 Norway
    • 8.5.8.1 Key Country Dynamics
    • 8.5.8.2 Regulatory Framework
    • 8.5.8.3 Pricing Analysis
    • 8.5.8.4 Norway Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.9 Sweden
    • 8.5.8.1 Key Country Dynamics
    • 8.5.8.2 Regulatory Framework
    • 8.5.8.3 Pricing Analysis
    • 8.5.8.4 Sweden Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6 Asia Pacific
  • 8.6.1 Asia Pacific Branded Generics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 8.6.2 Japan
    • 8.6.2.1 Key Country Dynamics
    • 8.6.2.2 Regulatory Framework
    • 8.6.2.3 Pricing Analysis
    • 8.6.2.4 Japan Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3 China
    • 8.6.3.1 Key Country Dynamics
    • 8.6.3.2 Regulatory Framework
    • 8.6.3.3 Pricing Analysis
    • 8.6.3.4 China Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4 India
    • 8.6.4.1 Key Country Dynamics
    • 8.6.4.2 Regulatory Framework
    • 8.6.4.3 Pricing Analysis
    • 8.6.4.4 India Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5 South Korea
    • 8.6.5.1 Key Country Dynamics
    • 8.6.5.2 Regulatory Framework
    • 8.6.5.3 Pricing Analysis
    • 8.6.5.4 South Korea Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.6 Australia
    • 8.6.6.1 Key Country Dynamics
    • 8.6.6.2 Regulatory Framework
    • 8.6.6.3 Pricing Analysis
    • 8.6.6.4 Australia Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.7 Thailand
    • 8.6.8.1 Key Country Dynamics
    • 8.6.8.2 Regulatory Framework
    • 8.6.8.3 Pricing Analysis
    • 8.6.8.4 Thailand Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7 Latin America
  • 8.8.1 Latin America Branded Generics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 8.8.2 Brazil
    • 8.8.2.1 Key Country Dynamics
    • 8.8.2.2 Regulatory Framework
    • 8.8.2.3 Pricing Analysis
    • 8.8.2.4 Brazil Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3 Argentina
    • 8.8.3.1 Key Country Dynamics
    • 8.8.3.2 Regulatory Framework
    • 8.8.3.3 Pricing Analysis
    • 8.8.3.4 Argentina Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8 Middle East & Africa
  • 8.8.1 Middle East & Africa Branded Generics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 8.8.2 South Africa
    • 8.8.2.1 Key Country Dynamics
    • 8.8.2.2 Regulatory Framework
    • 8.8.2.3 Pricing Analysis
    • 8.8.2.4 South Africa Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3 Saudi Arabia
    • 8.8.3.1 Key Country Dynamics
    • 8.8.3.2 Regulatory Framework
    • 8.8.3.3 Pricing Analysis
    • 8.8.3.4 Saudi Arabia Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.4 UAE
    • 8.8.4.1 Key Country Dynamics
    • 8.8.4.2 Regulatory Framework
    • 8.8.4.3 Pricing Analysis
    • 8.8.4.4 UAE Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.5 Kuwait
    • 8.8.5.1 Key Country Dynamics
    • 8.8.5.2 Regulatory Framework
    • 8.8.5.3 Pricing Analysis
    • 8.8.5.4 Kuwait Branded Generics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1 Sun Pharmaceutical Industries Ltd.
    • 9.5.1.1 Overview
    • 9.5.1.2 Financial Performance
    • 9.5.1.3 Product Benchmarking
    • 9.5.1.4 Strategic Initiatives
  • 9.5.2 Teva Pharmaceutical Industries Ltd.
    • 9.5.2.1 Overview
    • 9.5.2.2 Financial Performance
    • 9.5.2.3 Product Benchmarking
    • 9.5.2.4 Strategic Initiatives
  • 9.5.3 Cipla Ltd.
    • 9.5.3.1 Overview
    • 9.5.3.2 Financial Performance
    • 9.5.3.3 Product Benchmarking
    • 9.5.3.4 Strategic Initiatives
  • 9.5.4 Dr. Reddy's Laboratories Ltd.
    • 9.5.4.1 Overview
    • 9.5.4.2 Financial Performance
    • 9.5.4.3 Product Benchmarking
    • 9.5.4.4 Strategic Initiatives
  • 9.5.5 Lupin Ltd.
    • 9.5.5.1 Overview
    • 9.5.5.2 Financial Performance
    • 9.5.5.3 Product Benchmarking
    • 9.5.5.4 Strategic Initiatives
  • 9.5.6 Aurobindo Pharma Ltd.
    • 9.5.6.1 Overview
    • 9.5.6.2 Financial Performance
    • 9.5.6.3 Product Benchmarking
    • 9.5.6.4 Strategic Initiatives
  • 9.5.7 Torrent Pharmaceuticals Ltd.
    • 9.5.7.1 Overview
    • 9.5.7.2 Financial Performance
    • 9.5.7.3 Product Benchmarking
    • 9.5.7.4 Strategic Initiatives
  • 9.5.8 Viatris Inc.
    • 9.5.9.1 Overview
    • 9.5.9.2 Financial Performance
    • 9.5.9.3 Product Benchmarking
    • 9.5.9.4 Strategic Initiatives
  • 9.5.9 Sanofi
    • 9.5.7.1 Overview
    • 9.5.7.2 Financial Performance
    • 9.5.7.3 Product Benchmarking
    • 9.5.7.4 Strategic Initiatives
  • 9.5.10 Abbott
    • 9.5.8.1 Overview
    • 9.5.8.2 Financial Performance
    • 9.5.8.3 Product Benchmarking
    • 9.5.8.4 Strategic Initiatives